Some mouse tumours grew more slowly after researchers removed MDA5 from tumour cells, with immune cells contributing to the suppression. Depleting CD8 T cells reversed the effect. Experiments with human cells and associations in patient datasets support a biological mechanism, without any patient trial demonstrating benefit from MDA5 suppression.
MDA5 is a protein encoded by IFIH1 that helps sense viral RNA. Researchers used a CRISPR gene screen in mouse colorectal cancer cells, then compared cells lacking MDA5 in mice with intact or deficient immune systems. Some tumours grew more slowly in the immunocompetent animals across colon and liver tumour models. The contrast with immunodeficient mice pointed to an immune contribution beyond the cancer cell itself.[1]
The team measured CD8 T cells and other immune populations inside tumours. When CD8 T cells were experimentally depleted, the growth suppression associated with MDA5 loss was reversed. Tumour cells lacking MDA5 released more damage signals, including adenosine triphosphate (ATP) and HMGB1. The work also examined how dendritic cells presented tumour antigens and how the cells responded to immune signals such as TNF alpha and interferon gamma.[1]
Some mouse experiments paired the manipulation with immune checkpoint drugs. Cocultures containing human tumour cells showed related changes in antigen presentation, and patient databases were examined for associations between MDA5 levels and treatment response. These do not show that suppressing the gene in patients is beneficial or safe. Removing MDA5 only from experimental tumour cells differs from a treatment affecting the whole body, where its antiviral role matters.[1]
